Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scancell Holdings (GB:SCLP)
:SCLP
Holding GB:SCLP?
Track your performance easily
SCLP Stock Chart & Stats
Day’s Range― - ―
52-Week Range8.60p - 19.75p
Previous CloseN/A
Volume797.06K
Average Volume (3M)1.49M
Market Cap
£101.60M
Enterprise Value85.26M
Total Cash (Recent Filing)$2.67M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Jan 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,036,781,400
10 Day Avg. Volume1,723,220
30 Day Avg. Volume1,493,762
Standard Deviation0.25
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.77
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.96
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scancell Holdings News
PremiumCompany Announcements
Scancell’s Modi-1 Vaccine Shows Promising Early Results in Cancer Treatment
PremiumCompany Announcements
Scancell Holdings Secures £11.3 Million in Oversubscribed Offering
PremiumCompany Announcements
Scancell Holdings Secures £10.3 Million in Oversubscribed Funding
PremiumCompany Announcements
Scancell Holdings to Launch £9 Million Capital Raise
PremiumCompany Announcements
Scancell Holdings Announces Major Capital Raising Initiative
PremiumCompany Announcements
Scancell Holdings and Genmab Strengthen Partnership with New License
PremiumCompany Announcements
Scancell Holdings Shows Promising Results in SCOPE Trial
PremiumCompany Announcements
Scancell Holdings Moves Forward with Cancer TherapiesOptions Prices
Currently, No data available
---
Ownership Overview
SCLP FAQ
What was Scancell Holdings’s price range in the past 12 months?
Scancell Holdings lowest share price was 8.60p and its highest was 19.75p in the past 12 months.
What is Scancell Holdings’s market cap?
Scancell Holdings’s market cap is £101.60M.
When is Scancell Holdings’s upcoming earnings report date?
Scancell Holdings’s upcoming earnings report date is Jan 30, 2025 which is in 11 days.
How were Scancell Holdings’s earnings last quarter?
Scancell Holdings released its earnings results on Sep 24, 2024. The company reported -0.004p earnings per share for the quarter, missing the consensus estimate of N/A by -0.004p.
Is Scancell Holdings overvalued?
According to Wall Street analysts Scancell Holdings’s price is currently Overvalued.
Does Scancell Holdings pay dividends?
Scancell Holdings does not currently pay dividends.
What is Scancell Holdings’s EPS estimate?
Scancell Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings have?
Scancell Holdings has 1,036,781,400 shares outstanding.
What happened to Scancell Holdings’s price movement after its last earnings report?
Scancell Holdings reported an EPS of -0.004p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Scancell Holdings?
Currently, no hedge funds are holding shares in GB:SCLP
---
Scancell Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth £1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.11%
Trailing 12-Months
Company Description
Scancell Holdings
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
---
Technical Analysis
Sareum Holdings
―
ImmuPharma
―
Avacta Group plc
―
Futura Medical
―
Oxford BioDynamics
―
Bioventix
―
---